Case File
efta-efta00914005DOJ Data Set 9OtherFrom: Jeffrey Epstein <jeevacation®gmail.com>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00914005
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <jeevacation®gmail.com>
To: Harry Susman
Subject: Re:
Date: Thu, 30 Jun 2011 19:49:03 +0000
there point is that i only get the money invested as a loss, not the gain„ my position is that i withdrew the
increased amount and should calculate that number as my loss
On Thu, Jun 30, 2011 at 3:23 PM, Harry Susman <
> wrote:
If FTC does not pay US tax, what tax would it have had to pay if it had sold out of the High Grade Fund rather
than roll over?
Ham Susman
ent from my 'Phone
On Jun 30, 2011, at 11:24 AM, "Jeffrey Epstein" <jeevacation®gmail.com> wrote:
as you know I invested 15 million dollars in the high grade fund, it had risen to 20 million dollars when an
exchange offer was made, the offer allowed me to withdraw my funds in kind from high grade and make a
capital contribution to the enhanced leverage fund, jpm is taking the position that as their was no tax on the
transfer, ( in kind ), the loss should be calculated at 15 million vs 20 million„ I made the argument that the
tax consequences are not relevant and that the fact that the EL k-1 show a capital contribution of 20 million,
that should be theloss. Can you find me some case law that addresses these issues„ thanks,
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation®gmail.com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
EFTA00914005
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00914006
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.